Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virus

LONDON (Reuters) - The experimental COVID-19 vaccine developed by AstraZeneca and Oxford University would have a higher efficacy rate if trials were only measuring whether the shot prevents hospitalisation and severe disease, Oxford's vaccine chief said on Monday.

Reuters November 24, 2020 00:11:26 IST
Oxford COVID-19 vaccine efficacy would look higher if trial tested for severe virus

COVID-19 vaccine efficacy would look higher if trial tested for severe virus" src="https://images.firstpost.com/wp-content/uploads/reuters/11-2020/24/2020-11-23T103707Z_2_LYNXMPEGAM0KI_RTROPTP_2_HEALTH-CORONAVIRUS-ASTRAZENECA.jpg" alt="Oxford COVID19 vaccine efficacy would look higher if trial tested for severe virus" width="300" height="225" />

LONDON (Reuters) - The experimental COVID-19 vaccine developed by AstraZeneca and Oxford University would have a higher efficacy rate if trials were only measuring whether the shot prevents hospitalisation and severe disease, Oxford's vaccine chief said on Monday.

Speaking in a briefing, Andrew Pollard, director of the Oxford Vaccine Group, said it is hard to explain the different efficacy rates between the AstraZeneca/Oxford shot and the other vaccines developed by Pfizer and BioNTech and one by Moderna.

Pfizer-BioNTech and Moderna late-stage studies showed efficacy of more than 90%, while the British shot was on average 70% effective after testing its efficacy for all levels of the disease from severe to mild.

One reason may be that the companies are measuring for different things, Pollard said.

There may also be real differences between all the vaccines, he said.

(Reporting by Kate Kelland, Kate Holton and Guy Faulconbridge; Writing by Josephine Mason; Editing by Toby Chopra)

This story has not been edited by Firstpost staff and is generated by auto-feed.

Updated Date:

TAGS:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

Target holiday sales jump 17% as shoppers splurge online
Business

Target holiday sales jump 17% as shoppers splurge online

By Uday Sampath Kumar (Reuters) - Target Corp reported a 17.2% rise in comparable sales for the holiday season on Wednesday as its online sales more than doubled, thanks to faster deliveries and higher demand for home goods, electronics and beauty products.

S&P 500, Nasdaq tick higher on Intel boost
Business

S&P 500, Nasdaq tick higher on Intel boost

By Medha Singh and Devik Jain (Reuters) - The S&P 500 and the Nasdaq rose in choppy trading on Wednesday as Intel shares jumped thanks to a change in management while broader sentiment was muted after a recent run to record highs. Intel said it would replace Chief Executive Officer Bob Swan with VMware Inc CEO Pat Gelsinger next month

Bolivia signs contract with India's Serum Institute for 5 million AstraZeneca vaccine doses
Business

Bolivia signs contract with India's Serum Institute for 5 million AstraZeneca vaccine doses

By Danny Ramos LA PAZ (Reuters) - The Bolivian government said on Wednesday it had signed a contract with India's Serum Institute for the supply of 5 million doses of AstraZeneca's COVID-19 vaccine. President Luis Arce said that combined with a recent deal to buy 5.2 million Sputnik V vaccine doses from Russia, Bolivia now expected to be able to inoculate all of its vaccinable population. Both vaccines require two doses to be given, meaning they would be used to inoculate a total of 5.1 million people from Bolivia's 11.51 million-strong population.